PE20130236A1 - Composicion farmaceutica que comprende un derivado de amida o una sal farmaceuticamente aceptable del mismo - Google Patents

Composicion farmaceutica que comprende un derivado de amida o una sal farmaceuticamente aceptable del mismo

Info

Publication number
PE20130236A1
PE20130236A1 PE2012002375A PE2012002375A PE20130236A1 PE 20130236 A1 PE20130236 A1 PE 20130236A1 PE 2012002375 A PE2012002375 A PE 2012002375A PE 2012002375 A PE2012002375 A PE 2012002375A PE 20130236 A1 PE20130236 A1 PE 20130236A1
Authority
PE
Peru
Prior art keywords
composition
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
acid
Prior art date
Application number
PE2012002375A
Other languages
English (en)
Inventor
Yong Il Kim
Kyeong Soo Kim
Ki Young Jang
Yo Han Kim
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of PE20130236A1 publication Critical patent/PE20130236A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN COMPUESTO DERIVADO DE AMIDA DE FORMULA (I) EN UNA CANTIDAD DE 0,1 mg A 1,000 mg POR UNIDAD DE LA COMPOSICION; O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; Y B) UN ADITIVO ACIDO TAL COMO ACIDO ACETICO, ACIDO ADIPICO, ACIDO ASCORBICO, ACIDO PROPIONICO, ENTRE OTROS, EN UNA CANTIDAD DE 0,25 A 50 PARTES EN PESO BASADO EN 1 PARTE EN PESO DEL COMPUESTO DE FORMULA (I); TAMBIEN COMPRENDE UN EXCIPIENTE SELECCIONADO DE UN DILUYENTE, UN AGLUTINANTE, UN DESINTEGRANTE Y UN LUBRICANTE; ADEMAS LA COMPOSICION ESTA RECUBIERTA CON UN SUSTRATO DE RECUBRIMIENTO DE LIBERACION RAPIDA, UN SUSTRATO DE RECUBRIMIENTO ENTERICO Y UN SUSTRATO DE RECUBRIMIENTO DE LIBERACION SOSTENIDA. DICHA COMPOSICION TIENE UNA ESTABILIDAD MEJORADA Y ES ADECUADA PARA INHIBIR EL CRECIMIENTO DE CELULAS CANCEROSAS.DCI: POZIOTINIB
PE2012002375A 2010-06-11 2011-06-10 Composicion farmaceutica que comprende un derivado de amida o una sal farmaceuticamente aceptable del mismo PE20130236A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020100055549A KR101217526B1 (ko) 2010-06-11 2010-06-11 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물

Publications (1)

Publication Number Publication Date
PE20130236A1 true PE20130236A1 (es) 2013-03-18

Family

ID=45098550

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012002375A PE20130236A1 (es) 2010-06-11 2011-06-10 Composicion farmaceutica que comprende un derivado de amida o una sal farmaceuticamente aceptable del mismo

Country Status (26)

Country Link
US (1) US20130071452A1 (es)
EP (1) EP2580206B1 (es)
JP (1) JP5852105B2 (es)
KR (1) KR101217526B1 (es)
CN (1) CN102933573B (es)
AR (1) AR081870A1 (es)
AU (1) AU2011262662B2 (es)
BR (1) BR112012031510B1 (es)
CA (3) CA3012771C (es)
CL (1) CL2012003487A1 (es)
CO (1) CO6620015A2 (es)
DK (1) DK2580206T3 (es)
ES (1) ES2556457T3 (es)
HK (1) HK1181389A1 (es)
IL (1) IL223543A (es)
MA (1) MA34368B1 (es)
MX (1) MX2012014440A (es)
MY (1) MY164015A (es)
NZ (1) NZ605601A (es)
PE (1) PE20130236A1 (es)
PL (1) PL2580206T3 (es)
SG (1) SG185661A1 (es)
TW (1) TWI424995B (es)
UA (1) UA109281C2 (es)
WO (1) WO2011155793A2 (es)
ZA (1) ZA201300241B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
KR101317809B1 (ko) * 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR20140096571A (ko) * 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
WO2018213770A1 (en) * 2017-05-19 2018-11-22 Regents Of The University Of Minnesota Therapeutic methods
KR102227486B1 (ko) * 2017-06-30 2021-03-12 롯데정밀화학 주식회사 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법
EP3773551A4 (en) 2018-03-27 2022-03-23 Board of Regents, The University of Texas System COMPOUNDS WITH ANTITUMOR ACTIVITY AGAINST CANCER CELLS CARRYING HER2 EXON 19 MUTATIONS
SG11202012064PA (en) 2018-06-25 2021-01-28 Spectrum Pharmaceuticals Inc Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereof
WO2020053816A1 (en) * 2018-09-14 2020-03-19 Hanmi Pharmaceutical Co., Ltd. Crystalline forms of a quinazole compound and its hydrochloride salts
US11365189B2 (en) 2019-04-25 2022-06-21 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of tyrosine kinase
CA3138348A1 (en) 2019-05-09 2020-11-12 FUJIFILM Cellular Dynamics, Inc. Methods for the production of hepatocytes
US20220378790A1 (en) * 2019-10-24 2022-12-01 Hanmi Pharm Co., Ltd. Pharmaceutical preparation comprising an amide derivative inhibiting the growth of cancer cell and a pharmaceutical product containing the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR980008219A (ko) * 1996-07-16 1998-04-30 김상응 안정화된 주사제용 약제학적 조성물
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
WO2001021596A1 (en) * 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
CN1882570B (zh) * 2003-09-19 2010-12-08 阿斯利康(瑞典)有限公司 喹唑啉衍生物
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
BRPI0414735A (pt) * 2003-09-25 2006-11-21 Astrazeneca Ab derivado de quinazolina, composto, composição farmacêutica, uso de derivado de quinazolina, método para produzir um efeito anti-proliferativo em um animal de sangue quente, e, processo para a preparação de um derivado de quinazolina
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
JP5649157B2 (ja) * 2009-08-01 2015-01-07 住友電気工業株式会社 半導体素子およびその製造方法

Also Published As

Publication number Publication date
BR112012031510A2 (pt) 2016-11-08
ZA201300241B (en) 2014-03-26
JP5852105B2 (ja) 2016-02-03
CA3012771A1 (en) 2011-12-15
CA2801631A1 (en) 2011-12-15
TW201204711A (en) 2012-02-01
US20130071452A1 (en) 2013-03-21
EP2580206B1 (en) 2015-09-23
CN102933573A (zh) 2013-02-13
IL223543A (en) 2017-02-28
UA109281C2 (uk) 2015-08-10
AU2011262662B2 (en) 2015-06-25
EP2580206A4 (en) 2014-01-22
NZ605601A (en) 2014-11-28
CA3012771C (en) 2021-10-12
KR20110135685A (ko) 2011-12-19
AU2011262662A1 (en) 2013-01-31
TWI424995B (zh) 2014-02-01
EP2580206A2 (en) 2013-04-17
SG185661A1 (en) 2012-12-28
PL2580206T3 (pl) 2016-03-31
BR112012031510B1 (pt) 2021-06-22
WO2011155793A3 (en) 2012-04-26
ES2556457T3 (es) 2016-01-18
DK2580206T3 (en) 2016-01-11
CL2012003487A1 (es) 2013-02-22
CA2801631C (en) 2018-09-04
MY164015A (en) 2017-11-15
HK1181389A1 (en) 2013-11-08
MX2012014440A (es) 2013-02-26
WO2011155793A2 (en) 2011-12-15
CO6620015A2 (es) 2013-02-15
JP2013531648A (ja) 2013-08-08
CA3127906A1 (en) 2011-12-15
KR101217526B1 (ko) 2013-01-02
MA34368B1 (fr) 2013-07-03
CN102933573B (zh) 2014-12-24
AR081870A1 (es) 2012-10-24
RU2013100943A (ru) 2014-07-20

Similar Documents

Publication Publication Date Title
PE20130236A1 (es) Composicion farmaceutica que comprende un derivado de amida o una sal farmaceuticamente aceptable del mismo
UA105229C2 (uk) Фармацевтичний склад
PE20141056A1 (es) Metodos para el tratamiento de vhc
BR112014009146A8 (pt) formulações de etanercepte estabilizadas com aminoácidos
SG10201407538WA (en) Intravenous formulations of neurokinin-1 antagonists
UA97821C2 (en) Cyclized derivatives as eg-5 inhibitors
IN2014DN06132A (es)
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
AR098576A1 (es) Producto farmacéutico
TW200800951A (en) Substituted imidazole compounds as KSP inhibitors
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
MX2015013051A (es) 1-hidroxi-benzooxaboroles como agentes antiparasitarios.
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
JP2015506989A5 (es)
MX340360B (es) Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.
PH12015501752A1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors
GB201216469D0 (en) Stabilisation of viral particles
BR112012023178A2 (pt) ramidinas substituídas como antagonistas de receptor prostaglandina 2
AR086851A1 (es) Composicion farmaceutica que comprende un derivado de amida que inhibe el crecimiento de celulas con cancer y lubricante de sal no metalica, metodo para preparar una formulacion de la composicion farmaceutica y metodo para estabilizar dicha composicion
BR112012014721A2 (pt) composição de hormônio do crescimento
MX2009003794A (es) Composicion de prostaglandina e estabilizada.
EA201490363A1 (ru) Новые составы на основе (триметоксифениламино)пиримидинилов
BR112012023039A2 (pt) pirimidina substituída como um antagonista de receptor prostaglandina d2
MX2013002694A (es) Derivados de tetrahidroquinolina usados como activadores de proteina cinasa activada por monofosfato de adenosina.
NZ603783A (en) Pharmaceutical aqueous compositions comprising lipoic acid as an antioxidant

Legal Events

Date Code Title Description
FG Grant, registration